David Pérol

Université Claude Bernard Lyon 1 — France

Biochemistry, Genetics and Molecular Biology · Life Sciences

49h-index12.2kcitations470works2.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(60), Sarcoma Diagnosis and Treatment(55), Lung Cancer Treatments and Mutations(45), Cancer Treatment and Pharmacology(44), Cancer Immunotherapy and Biomarkers(40)

Publications468 total

RWD56 Descriptive Comparison of Patient Characteristics and Treatment Patterns in Metastatic NSCLC: US and France Cohorts to Inform Transportability
Value in Health·2025
Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial – BREASTIMMUNE-03
The Breast·2025Open Access
Enhancing confidence in complex health technology assessments by using real-world evidence: highlighting existing strategies for effective drug evaluation
BMC Medical Research Methodology·2025Open Access
Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort
ESMO Open·2025· 1 citedOpen Access
Compression therapy with surgical gloves compared to cold therapy with frozen gloves in preventing paclitaxel-induced peripheral neuropathy: Results from the prospective ELEGANT trial in patients with breast cancer
European Journal of Cancer·2025
Reply to: Critical evaluation of the ProfiLER-02 study design and outcomes
Nature Medicine·2025
2693MO COTESARC: A multicentre, open-label, phase I-II evaluating the combination of MEK and PDL-1 inhibitors in patients with advanced soft tissue sarcoma (STS)
Annals of Oncology·2025
LBA98 Final results of the RAR-IMMUNE study: A randomized, comparative, prospective, multicenter phase III trial of the efficacy of nivolumab + ipilimumab (N+I) versus pazopanib (P) in patients (pt) with advanced sarcoma (S) of rare subtype
Annals of Oncology·2025Open Access
515P Real world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR+/HER2- metastatic breast cancer in the ESME-MBC cohort
Annals of Oncology·2025
966P IMMUNONET: A proof of concept phase II evaluating NP137 as add on therapy in solid tumors under standard immunotherapies: Interim analysis of primary and secondary refractory cohorts
Annals of Oncology·2025
216eP MegaMOST - A multicenter, open-label, molecularly selected bayesian phase II platform trial in advanced or metastatic solid tumors: Final analysis of the trametinib cohort
Annals of Oncology·2025
587P Recent nationwide overall survival trends across subtypes in 33,044 patients with metastatic breast cancer in the French ESME cohort
Annals of Oncology·2025
Clinical benefit of adding cyanoacrylate glue during PICC line insertion compared to standard procedure in outpatient cancer patients: Results from the randomized prospective trial PICCandGLUE
The Journal of Vascular Access·2025· 1 cited
Reply to Letter to the Editor “Long-term follow-up of PAOLA-1 and the evolving landscape of post-PARP treatment strategies in ovarian cancer” by Arenhardt and Nogueira-Rodrigues
Annals of Oncology·2025· 1 cited
Systematic referral to palliative care in patients attending dedicated emergency units from French comprehensive anticancer centres: the prospective multicentre randomised comparative clinical trial PALLU
BMJ Open·2025Open Access
Integrating Environmental Impact in Health Technology Assessment: An Exploratory Study
PharmacoEconomics·2025· 3 citedOpen Access
Paediatric palliative care medical hotline: retrospective database study
BMJ Supportive & Palliative Care·2025
Abstract RF3-03: Nivolumab + Ipilimumab (NIVO+IPI) compared to capecitabine for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy – Final results of BreastImmune-03, a multicenter randomized open-label phase II trial
Clinical Cancer Research·2025· 1 cited
Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial
Annals of Oncology·2025· 3 citedOpen Access
IMMUNONET: A multicenter, open-label, proof-of-concept phase II trial evaluating NP137 as add-on therapy in advanced/metastatic solid tumors treated with standard immunotherapies.
Journal of Clinical Oncology·2025
page 1 of 24Next →

Frequent Co-authors

Jean‐Yves Blay(22), Isabelle Ray‐Coquard(17), Sylvie Chabaud(14), Christine Chevreau(13), Thomas Bachelot(9), Philippe A. Cassier(9), Florence Duffaud(9), María Rios(9), C. Carrié(9), Olivier Trédan(8), François Bertucci(7), Claire Cropet(6), Axel Le Cesne(6), Didier Cupissol(6), Sylvie Négrier(6), Bernard Escudier(6), Alain Ravaud(6), Axel Le Cesne(5), M. Pérol(5), L. Falchero(5)